Growth hormone and ovulation: is there an indication for treatment of infertile women with growth hormone?

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin), published as a randomized controlled trial.

The researchers have explored the use of growth hormone (GH) for ovulation induction and ovarian stimulation for in vitro fertilization and embryo transfer (IVF-ET).

The patients were gonadotrophin deficient and, for the main part, hypopituitary.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Anovulation, Embryo Transfer, Fertilization in Vitro, Growth Hormone, Infertility, Female, Menotropins and Ovulation Induction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin).

The publication is from 1992 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.